AFM
Sterile
Ophthalmic Suspension

Composition:
Each ml contains: Fluorometholone
1 mg with liquifilm (polyvinyl alcohol) 14 mg.
Pharmacology:
Corticosteroids,
such as fluorometholone, inhibit the inflammatory response
to a variety of inciting agents. They inhibit the edema, fibrin
deposition, capillary dilation, leukocyte migration, phagocytic
activity, capillary proliferation, fibroblast proliferation,
deposition of collagen, and scar formation associated with
inflammation.
Corticosteroids
are thought to act by the induction of phospholipase A2 inhibitory
proteins, collectively called lipocortins. It is postulated
that these proteins control the biosynthesis of potent mediators
of inflammation such as prostaglandins and leukotrienes by
inhibiting the release of their common precursor arachidonic
acid. Arachidonic acid is released from membrane phospholipids
by phospholipase A2. Adrenocorticosteroids and their derivatives
are capable of producing a rise in intraocular pressure.
Indications:
For steroid responsive
inflammation of the palpebral and bulbar conjunctiva, cornea
and anterior segment of the globe.
Dosage & Administration:
1 to 2 drops
instilled into the conjunctival sac 2-4 times daily. During
the initial 24 to 48 hours the dosage may be safely increased
to 2 drops every hour. Care should be taken not to discontinue
therapy prematurely. Shake well before use.
Side-effects:
Elevation of
intraocular pressure with possible development of glaucoma,
and frequent optic nerve damage, posterior subcapsular cataract
formation, secondary ocular infection from pathogens liberated
from ocular tissues, perforation of the globe delayed wound
healing.
Contraindications:
Acute superficial
herpes simplex keratitis, fungal diseases of ocular structures,
vaccinia, varicella and most other viral diseases of the cornea
and conjunctiva, tuberculosis of the eye, hypersensitivity
to the constituents of this medication.
Warnings:
1.
If sensitivity or other untoward reactions occur, discontinue
the medication.
2.
As fungal infections of the cornea have been reported coincidentally
with long-term local steroid applications, fungal invasion
may be suspected in any persistent corneal ulceration where
a steroid has been used, or is in use, over a prolonged period
of time.
3.
Various ocular diseases and long-term use of topical corticosteroids
have been known to cause corneal and scleral thinning. Use
of topical corticosteroids in the presence of thin corneal
or scleral tissue may lead to perforation.
4.
Acute purulent untreated infections of the eye may be masked,
enhanced, or activated by the presence of steroid medication.
Secondary ocular infection may occur from pathogens liberated
from ocular tissues.
5.
Use of steroid medication in the treatment of patients with
a history of herpes simplex requires great caution, frequent slit-lamp microscopy is required.
6.
Reports in the literature indicate that posterior subcapsular
lenticular opacities have occurred after heavy or prolonged
use of topical ophthalmic corticosteroids.
7.
Prolonged use of topical steroids may increase intraocular
pressure. Although currently available data indicate that
intraocular pressure rise is generally not a problem with
patients being treated with fluorometholone 0.1%, their intraocular
pressure should be checked periodically.
Use in pregnancy and lactation:
Safety of the use of topical steroids during pregnancy
and lactation have not been established.
Use in children:
Safety and effectiveness
in children have not been established.
Additional Information:
-
Close
the bottle immediately after use.
-
Do
not use for more than one month after first opening.
-
Store
at room temperature.
-
Keep
all medicine out of the reach of children.
-
To
be dispensed only by or on the prescription of a registered
physician.
Packing:
AFM Ophthalmic Suspension
is supplied in 5 ml plastic dropper bottle.